Laurine Lagache | Oncology | Innovative Research Award

Published on by Cell Biologist

 

Innovative Research Award

Laurine Lagache
PRISM – Inserm U1192, France

Laurine Lagache
Affiliation PRISM – Inserm U1192
Country France
Scopus ID 59161941000
Documents 6
Citations 12
h-index 3
Subject Area Oncology
Event World Cell Biologist Awards
ORCID 0009-0000-4442-6642

Laurine Lagache is a researcher affiliated with PRISM – Inserm U1192 in France, with a research profile situated within the field of oncology. Her documented scholarly record comprises 6 documents, 12 citations, and an h-index of 3 according to the supplied Scopus profile information. [1] Her research context is relevant to contemporary cell biology and cancer research, disciplines in which cellular mechanisms, molecular interactions, disease progression, and therapeutic responses are closely interconnected. [2]

Abstract

The Innovative Research Award profile for Laurine Lagache presents a concise academic overview of a researcher working in oncology at PRISM – Inserm U1192, France. The profile is based on the supplied researcher identification and bibliometric information, including six indexed documents, twelve citations, and an h-index of three. [1] The research domain is positioned within the broader scientific landscape of oncology and cell biology, where investigation of cellular and molecular mechanisms contributes to understanding disease biology and developing improved approaches to diagnosis, prognosis, and treatment. [2]

Keywords

Laurine Lagache; Innovative Research Award; oncology; cell biology; cancer research; PRISM – Inserm U1192; biomedical research; molecular oncology; research impact; scientific innovation.

Introduction

Oncology is a multidisciplinary research field encompassing the biological mechanisms responsible for cancer development, progression, dissemination, and response to treatment. Modern cancer research increasingly integrates cellular biology, molecular biology, genetics, immunology, bioinformatics, and translational science to characterize disease processes at multiple levels. [2]

Research Profile

The supplied bibliometric profile identifies Laurine Lagache under Scopus Author ID 59161941000. The reported record contains 6 documents, 12 citations, and an h-index of 3. [1] These indicators provide quantitative information about indexed scholarly output and citation activity, but they should be interpreted in conjunction with publication quality, authorship contribution, research relevance, and the scientific context of the work.

Research Contributions

The available information establishes oncology as the principal subject area associated with the researcher profile. On this basis, the relevant contribution can be considered within the wider scientific objective of improving knowledge of cancer biology and its cellular and molecular foundations. However, the supplied data do not provide sufficient evidence to attribute a particular discovery, technique, therapeutic intervention, or clinical finding to Laurine LAGACHE. [4]

Publications

The supplied Scopus profile records 6 documents associated with the researcher identifier. [1] The available input does not provide individual publication titles, journals, publication years, author positions, or article-level DOI identifiers. Consequently, no specific publication is attributed to Laurine LAGACHE in this profile beyond the supplied bibliometric record.[3] [5]

Research Impact

The reported citation count of 12 and h-index of 3 indicate measurable scholarly citation activity within the supplied Scopus record. [1] Citation indicators can be useful for understanding the visibility of research outputs, although they do not independently establish the quality, originality, societal value, or practical significance of research. [3]

Award Suitability

Based on the supplied information, Laurine Lagache research profile is aligned with the scientific scope of an Innovative Research Award through its stated focus on oncology and its documented scholarly activity. The profile provides identifiable affiliation, research area, indexed documents, citations, h-index, and a persistent ORCID identifier, which together provide a basis for academic profile verification. [1] [3]

Conclusion

Laurine Lagache is presented as an oncology researcher affiliated with PRISM – Inserm U1192 in France. The supplied profile records 6 Scopus-indexed documents, 12 citations, and an h-index of 3, together with Scopus Author ID 59161941000 and ORCID 0009-0000-4442-6642. [1] [3]

References

  1. Elsevier. (n.d.). Scopus author details: Laurine LAGACHE, Author ID 59161941000. Scopus.
    https://www.scopus.com/pages/authors/59161941000
  2. L Lagache,D Simon, GS Horkovics-Kováts, et al. (2025). Subcellular-Resolution Molecular Pathology by Laser Ablation–Rapid Evaporative Ionization Mass Spectrometry.
    https://pubs.acs.org/ancham/article-abstract/97/32/17433/3622698
  3. L Lagache, J Salzet, I Fournier, M Salzet. (2026). Beyond Darwin: reactive heredity, burst-drift dynamics and eco‑evolutionary control of cancer.
    https://link.springer.com/article/10.1186/s12943-026-02683-w
  4. A Goossen, L Lagache, et al. (2026). A Universal Modular High-Plex MALDI Mass Spectrometry Imaging Platform.
    https://www.researchsquare.com/article/rs-9525563/v1
  5. L Lagache, M Salzet. (2026). Metastasis as a breakdown of the multicellular social contract.
    https://link.springer.com/article/10.1007/s10555-026-10352-z

Prof. JY Guo | Cancer Cell Biology | Women Researcher Award

Published on by Cell Biologist

Prof. JY Guo | Cancer Cell Biology | Women Researcher Award

Youjiang Medical University for Nationalities | China

A cross-disciplinary researcher specializing in pharmaceutical and analytical chemistry, with expertise in integrating traditional herbal medicine and modern nanotechnology. Research focuses on isolating bioactive compounds, developing hydrogel-based medical materials, and designing nanoparticle and vaccine systems for cancer therapy. Has led multiple national and regional research projects, published extensively in peer-reviewed journals, and contributed to advancements in biomaterials and drug development. Work also includes metabolomics and mass spectrometry imaging. Actively involved in academic collaborations, editorial responsibilities, and professional organizations, supporting innovation in pharmaceutical sciences and translational medicine.

 

Citation Metrics (Scopus)

800
600
400
200
100
50
0

Citations
718

Documents
16

h-index
10

Citations

Documents

h-index

Featured Publications

Mr. Rahul Das Gupta | Cancer Cell Biology | Editorial Board Member

Published on by Cell Biologist

Mr. Rahul Das Gupta | Cancer Cell Biology | Editorial Board Member

Maulana Abul Kalam Azad University of Technology | India

Rahul Das Gupta is a biotechnology researcher with expertise in cancer biology, nanomedicine, and computational drug discovery. His work focuses on exosome-based liquid biopsy for early brain cancer detection and in-silico screening of plant-derived anticancer compounds targeting oncogenic pathways. He has synthesized bio-metallic nanoparticles using medicinal plant extracts and evaluated their antimicrobial and cytotoxic potential through experimental and computational approaches, including EGFR and VEGFR interaction studies. Skilled in molecular biology, cell culture, bioinformatics, and advanced characterization techniques, he integrates laboratory research with computational analysis. His publication in Biochemical and Biophysical Research Communications highlights his contributions to translational cancer research.

Citation Metrics (Google Scholar)

2
1.5
1
0.5
0

Citations
2

h-index
1

i10-index
0

Citations

h-index

i10-index

Featured Publications

May Morris | Cancer Cell Biology | Women Researcher Award

Published on by Cell Biologist

Dr. May Morris | Cancer Cell Biology | Women Researcher Award

IBMM / CNRS | France

Dr. May C. Morris is a CNRS Research Director (DR2) leading the “Biosensors and Inhibitors Group” within the Cellular Pharmacology Team at IBMM, University of Montpellier. Her research focuses on cell cycle biology, cancer, kinases and phosphatases, and peptide/protein biochemistry. She specializes in biophysical studies of protein interactions, fluorescent biosensor engineering, cell-penetrating peptide technologies, intracellular targeting, and high-throughput screening of small molecules. Dr. Morris has extensive experience in designing peptide and allosteric kinase inhibitors, as well as advanced cell culture and fluorescence imaging. Her career includes leadership roles at CNRS and postdoctoral research at the Scripps Research Institute.

Citation Metrics (Scopus)

8000
6000
4000
2000
200
100
0

Citations
7,564

Documents
94

h-index
36

Citations

Documents

h-index

Featured Publications

Sakarie Mustafe Hidig | Cancer Cell Biology | Research Excellence Award

Published on by Cell Biologist

Dr. Sakarie Mustafe Hidig | Cancer Cell Biology | Research Excellence Award

Zhejiang University School of Medicine | United Kingdom

Dr. Sakarie Mustafe Hidig is a General Surgeon, Clinical Researcher, and Editor-in-Chief affiliated with Zhejiang University School of Medicine and the Research Center at Hargeisa Group Hospital. He serves as the UK Country Coordinator for the International Institute of Knowledge Management (TIIKM) and is an active member of the China Medical Association, Somali Medical Association, and the Scholars Academic and Scientific Society. Dr. Hidig has earned multiple international honors, including the SHEN Best Researcher Awards, GCDMSE-2024, and ISSN Research Awards. With over 70 published papers, 280+ SCI editorial handling experiences, and 14 research projects, his work spans general, gastrointestinal, trauma, emergency, hepatobiliary, and pancreatic surgery. He also contributes as an editor for major journals such as PLOS One Medicine, Annals of Medicine and Surgery, Obesity Surgery, and JMIR Public Health and Surveillance. His research interests include surgical oncology, hepatology, pancreatic cancer, and public health.

Citation Metrics (Scopus)

40

30

20

10

0

Citations
12

Documents
7

h-index
2

Citations
Documents
h-index



View Scopus Profile

Featured Publication

Hongjin Liu | Cancer Cell Biology | Research Excellence Award

Published on by Cell Biologist

Dr. Hongjin Liu | Cancer Cell Biology | Research Excellence Award

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | China

Hongjin Liu is a medical oncologist whose research centers on cancer biology, therapeutic resistance, and tumorigenesis. His work spans molecular oncology, hepatocellular carcinoma, and mechanisms of somatic mutagenesis across human tissues. He has contributed to high-impact studies published in Nature and Signal Transduction and Targeted Therapy, including investigations uncovering the landscape of somatic mutations in normal tissues and the critical role of VAV2 in DNA repair and radiotherapy resistance. His research also explores noncoding RNA–mediated regulatory networks in liver cancer, notably identifying the oncogenic function of ELF3-AS1 through its modulation of the miR-98-5p/CPSF4 axis. Collectively, his publications provide important insights into genomic instability, tumor microenvironment dynamics, and potential molecular targets for improving therapeutic outcomes. His translational research aims to bridge molecular mechanisms with clinical oncology to support precision cancer treatment and advance strategies for overcoming therapy resistance.

Profile: Orcid

Featured Publications: 

1. Ge, P., Niu, S., Fang, M., Xu, Q., Zhang, W., Xu, J., Yang, F., Wang, Y., Shi, T., & Liu, H. (2025). ELF3-AS1 promotes the carcinogenesis of hepatocellular carcinoma cells by inhibiting miR-98-5p/CPSF4 axis. Nucleosides, Nucleotides & Nucleic Acids.

2. Zhang, W., Liu, Z., Liu, H., Huang, Z., Huang, X., Xu, L., Che, X., & Zhan, Z. (2025). The impact of immune checkpoint inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: A meta-analysis. Frontiers in Immunology.

3. Liu, W., Miao, C., Zhang, S., Liu, Y., Niu, X., Xi, Y., Guo, W., Chu, J., Lin, A., Liu, H., Yang, X., Chen, X., Zhong, C., Ma, Y., Wang, Y., Zhu, S., Liu, S., Tan, W., Lin, D., & Wu, C. (2021). VAV2 is required for DNA repair and implicated in cancer radiotherapy resistance. Signal Transduction and Targeted Therapy, 6(9), 2906–2919.

4. Li, R., Di, L., Li, J., Fan, W., Liu, Y., Guo, W., Liu, W., Liu, L., Li, Q., Chen, L., Chen, Y., Miao, C., Liu, H., Wang, Y., Ma, Y., Xu, D., Lin, D., Huang, Y., Wang, J., Bai, F., & Wu, C. (2021). A body map of somatic mutagenesis in morphologically normal human tissues. Nature, 597(7876), 398–403.

5. Chen, Y., Zeng, Q., Liu, X., Fu, J., Zeng, Z., Zhao, Z., Liu, Z., Bai, W., Dong, Z., & Liu, H. (2018). LINE-1 ORF-1p enhances the transcription factor activity of pregnenolone X receptor and promotes sorafenib resistance in hepatocellular carcinoma cells. Cancer Management and Research, 10, 6345–6358.

Yanqi Dang | Cancer Cell Biology | Editorial Board Member

Published on by Cell Biologist

Mr. Yanqi Dang | Cancer Cell Biology | Editorial Board Member

Institute of Digestive Diseases, Longhua Hospital, China-Canada Center of Research for Digestive Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 200032 | China

The researcher focuses on the epigenetic regulation of metabolic diseases and tumorigenesis, with major contributions in colorectal cancer (CRC) diagnostics, mechanisms, and traditional Chinese medicine (TCM)-based interventions. In early CRC detection, the team performed transfer RNA (tRNA) sequencing and identified two key tRFs—tRF-Tyr-GTA-081 (downregulated) and tRF-Ala-AGC-060 (upregulated)—whose combined diagnostic model demonstrated strong performance for colorectal neoplastic lesions and cancer, outperforming traditional markers such as CEA and CA199. Multi-omics analyses of mRNAs, miRNAs and circRNAs identified three circRNAs with predictive value for adenoma–carcinoma transition. Through DNA hydroxymethylation sequencing, ZW10 emerged as a prognostic-related marker, and its circulating hydroxymethylation level showed high accuracy for early CRC detection. Mechanistic studies revealed that METTL3 regulates CRB3 in an m6A-dependent manner to modulate HIPPO signaling, while DNMT3B- and TET2-mediated epigenetic modifications jointly control PGC-1α to promote CRC progression. In therapeutic research, Scutellaria baicalensis Tang, Sijunzi Tang, and related monomers are under investigation for anti-CRC effects. In metabolic disease research, Ling-Gui-Zhu-Gan decoction and cinnamaldehyde were shown to improve steatosis and insulin resistance in NAFLD, supporting the TCM concept of “phlegm-beverage.” Current studies focus on lean NAFLD, demonstrating that METTL14 regulates TIM3 to influence disease development, and that GJLZ decoction alleviates steatosis and inflammation by enhancing this pathway.

Profile: Scopus

Featured Publications:

Ma, J., …, & al. (2025). Regulation of histone H3K27 methylation in inflammation and cancer.

Waldemar Debinski | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Waldemar Debinski | Cancer Cell Biology | Best Researcher Award

Wake Forest School of Medicine | United States

Dr. Waldemar Debinski, M.D., Ph.D., is a distinguished neuroscientist and cancer researcher recognized for his pioneering work in brain tumor biology and targeted molecular therapies. His research focuses on understanding the molecular mechanisms that drive the development and progression of malignant brain tumors, with a particular emphasis on gliomas. Dr. Debinski has significantly contributed to the development of novel targeted therapeutics, including receptor-directed cytotoxins and biologics designed to selectively eliminate tumor cells while sparing healthy tissues. His investigations bridge molecular oncology, translational science, and clinical application, aiming to improve therapeutic outcomes for patients with brain cancers. Throughout his career, he has integrated insights from physiology, molecular biology, and pharmacology to develop translational approaches that move from laboratory discovery to clinical implementation. His extensive research has advanced the understanding of tumor-specific receptors and intracellular signaling pathways, contributing to innovative strategies in cancer immunotherapy and precision medicine. Dr. Debinski’s work exemplifies the integration of basic and clinical research toward the development of next-generation treatments for central nervous system malignancies, positioning him as a leading figure in neuro-oncology and translational cancer research.

Profile: Scopus

Featured Publications:

Wocial, B., Januszewicz, W., Siedlecki, J., Feltynowski, T., & Debinski, W. (1982). Alterations in plasma dopamine-β-hydroxylase and catecholamine concentrations during surgical removal of pheochromocytoma. Endocrinologie, 79, 131–139.

Debinski, W., & Wocial, B. (1982). Various aspects of sodium metabolism in hypertension [in Polish]. Polski Tygodnik Lekarski, 37, 1339–1342.

Ignatowska-Świtalska, H., Debinski, W., & Chojnowski, K. (1983). The role of certain hormonal factors in arterial hypertension [in Polish]. Materia Medica Polona, 15, 74–86.

Wasawska, T., Feltynowski, T., Majewska, Z., Januszewicz, W., Sobolewska-Karwowska, A., Wocial, B., & Debinski, W. (1984). Pheochromocytoma: Description of two cases with an unusual clinical picture [in Polish]. Polski Tygodnik Lekarski, 39, 261–263.

Czarkowski, M., & Debinski, W. (1984). Sodium and primary arterial hypertension [in Polish] (Review). Kardiologia Polska, 27, 967–976.

Wocial, B., Debinski, W., Jablonska-Skwicinska, E., Feltynowski, T., Chodakowska, J., Kozakowska, E., & Januszewicz, W. (1984). Sodium content of erythrocytes in patients with arterial hypertension [in Polish]. Polski Archiwum Medycyny Wewnetrznej, 72, 167–174.

Garcia, R., Debinski, W., Gutkowska, J., Kuchel, O., Thibault, G., Genest, J., & Cantin, M. (1985). Gluco- and mineralocorticoids may regulate the natriuretic effect and the synthesis and release of atrial natriuretic factor by the rat atria in vivo. Biochemical and Biophysical Research Communications, 131, 806–814.

Debinski, W., Kuchel, O., Garcia, R., Buu, N. T., Racz, K., Cantin, M., & Genest, J. (1986). Atrial natriuretic factor inhibits sympathetic activity in one-kidney, one-clip hypertension in the rat. Proceedings of the Society for Experimental Biology and Medicine, 181, 173–177.

Debinski, W., Kuchel, O., Buu, N. T., Garcia, R., Cantin, M., & Genest, J. (1986). Involvement of the adrenal glands in the action of the atrial natriuretic factor. Proceedings of the Society for Experimental Biology and Medicine, 181, 318–324.

Debinski, W., Gutkowska, J., Kuchel, O., Racz, K., Buu, N. T., Cantin, M., & Genest, J. (1986). ANF-like peptide(s) in the peripheral autonomic nervous system. Biochemical and Biophysical Research Communications, 134, 279–284.

Amirhosein Kefayat | Cancer Cells | Best Researcher Award

Published on by Cell Biologist

Dr. Amirhosein Kefayat | Cancer Cells | Best Researcher Award

Edinburgh of University | United Kingdom

Dr. Amirhosein Kefayat is a clinical research fellow at the Institute of Genetics and Cancer, University of Edinburgh, with over fourteen years of dedicated experience in translational and clinical cancer research. Since his early days in medical school, he has pursued a strong passion for advancing oncology through both laboratory and clinical investigations, contributing to more than 60 peer-reviewed publications that have collectively garnered over 2,300 citations, with a Google Scholar H-index of 28. His research spans biomaterials, nanomedicine, wound healing, immunoinformatics, and cancer vaccine design, with several of his papers ranking among the top 1% most-cited in their respective years of publication. Notably, his work on innovative wound dressings, cancer-testis antigen vaccines, and gold nanoclusters for radiosensitization has made significant impacts within the fields of biomaterials and cancer therapeutics. Alongside his research, he is currently advancing his academic qualifications through a Postgraduate Certificate of Academic Practice at the University of Edinburgh and Associate Principal Investigator Training with NIHR. Recognized among the top 0.5% of cancer researchers worldwide, his career reflects a consistent commitment to bridging basic science and clinical application to improve patient care.

Profiles: Google Scholar | Scopus | Orcid

Featured Publications:

Eskandarinia, A., Kefayat, A., Agheb, M., Rafienia, M., Amini Baghbadorani, M., & Navid, S. (2020). A novel bilayer wound dressing composed of a dense polyurethane/propolis membrane and a biodegradable polycaprolactone/gelatin nanofibrous scaffold. Scientific Reports, 10(1), 3063.

Eskandarinia, A., Kefayat, A., Gharakhloo, M., Agheb, M., Khodabakhshi, D., & Rafienia, M. (2020). A propolis enriched polyurethane-hyaluronic acid nanofibrous wound dressing with remarkable antibacterial and wound healing activities. International Journal of Biological Macromolecules, 149, 467–476.

Safavi, A., Kefayat, A., Mahdevar, E., Abiri, A., & Ghahremani, F. (2020). Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches. Vaccine, 38(48), 7612–7628.

Khodabakhshi, D., Eskandarinia, A., Kefayat, A., Rafienia, M., Navid, S., & Karbasi, S. (2019). In vitro and in vivo performance of a propolis-coated polyurethane wound dressing with high porosity and antibacterial efficacy. Colloids and Surfaces B: Biointerfaces, 178, 177–184.

Eskandarinia, A., Kefayat, A., Rafienia, M., Agheb, M., Navid, S., & Ebrahimpour, K. (2019). Cornstarch-based wound dressing incorporated with hyaluronic acid and propolis: In vitro and in vivo studies. Carbohydrate Polymers, 216, 25–35.

Evgeny Deforzh | Cancer | Best Researcher Award

Published on by Cell Biologist

Dr. Evgeny Deforzh | Cancer | Best Researcher Award

Brigham and Women’s Hospital, Harvard University | United States

Dr. Evgeny Deforzh is a molecular biologist whose work focuses on the regulation of RNA, microRNAs, chromatin dynamics, and their roles in cancer and neurological disease. After earning his B.S. and M.S. in Biology from Saint Petersburg State University and a Ph.D. in Molecular Biology from Paris‑Saclay University, he completed postdoctoral research as a Research Fellow and subsequently served as Instructor in Neurology at Brigham & Women’s Hospital. His peer‑reviewed contributions include insights into how WEE1 regulators switch roles in cell cycle control, protection of cyclin mRNAs from translational repression, the impact of glioblastoma‑derived extracellular vesicles on astrocyte transformation, and the nuclear modulation of splicing by oncogenic microRNAs. More recently, his work has elucidated promoter/enhancer RNA regulation of super‑enhancers, and miRNA pathways as therapeutic targets in gliomas and meningiomas. To date, Dr. Deforzh has published ~15–20 independent original research articles (first‑, co‑first, or senior‑author) with many additional co‐authored papers. His publications have been cited in the literature ~800‑1,200 times, giving him an approximate h‑index of 12–15. His research has advanced understanding of RNA regulatory networks in cancer and offers potential translational pathways for diagnostics and therapy.

Profiles: Google Scholar | Scopus

Featured Publications:

Zeng, A., Wei, Z., Rabinovsky, R., Jun, H. J., El Fatimy, R., Deforzh, E., & Arora, R. (2020). Glioblastoma-derived extracellular vesicles facilitate transformation of astrocytes via reprogramming oncogenic metabolism. iScience, 23(8), 101420.

Deforzh, E., Uhlmann, E. J., Das, E., Galitsyna, A., Arora, R., Saravanan, H., … (2022). Promoter and enhancer RNAs regulate chromatin reorganization and activation of miR-10b/HOXD locus, and neoplastic transformation in glioma. Molecular Cell, 82(10), 1894–1908.e5.

El Fatimy, R., Zhang, Y., Deforzh, E., Ramadas, M., Saravanan, H., Wei, Z., … (2022). A nuclear function for an oncogenic microRNA as a modulator of snRNA and splicing. Molecular Cancer, 21(1), 17.

Poller, W., Sahoo, S., Hajjar, R., Landmesser, U., & Krichevsky, A. M. (2023). Exploration of the noncoding genome for human-specific therapeutic targets—Recent insights at molecular and cellular level. Cells, 12(22), 2660.

Deforzh, E., Vargas, T. R., Kropp, J., Vandamme, M., Pinna, G., & Polesskaya, A. (2016). IMP-3 protects the mRNAs of cyclins D1 and D3 from GW182/AGO2-dependent translational repression. International Journal of Oncology, 49(6), 2578–2588.

Kratassiouk, G., Pritchard, L. L., Cuvellier, S., Vislovukh, A., Meng, Q., … (2016). The WEE1 regulators CPEB1 and miR-15b switch from inhibitor to activators at G2/M. Cell Cycle, 15(5), 667–677.